Printer Friendly

Breast decision.

Breast decision

The Food and Drug Administration has approved a drug as a follow-up for certain women who have had breast cancer surgery. The treatment was endorsed last fall by a National Institutes of Health consensus conference.

Despite advances in surgical and radiation treatment, breast cancer continues to kill about 38,000 U.S. women each year. The newly approved drug. Stuart Pharmaceuticals' tamoxifen citrate, has been shown to decrease the rate of cancer spread and death in postmenopausal women whose breat cancer cells depend on the hormone estrogen for growth. Tamxoifen works by blocking estrogen receptor sites on breast cancer cells throughout the body.
COPYRIGHT 1986 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1986, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:approval of drug for post-surgery treatment
Publication:Science News
Date:Jan 11, 1986
Previous Article:Another cell victim of AIDS virus?
Next Article:Brain food.

Related Articles
Beating breast cancer: researchers are looking beyond conventional surgeries and chemotherapy.
New treatment may reduce breast surgeries.
Tamoxifen clears hurdle to preventive use.
Irreconcilable differences.
A hopeful clue for resistant MS.
What we are doing about symptoms that can't be measured easily.
New litigation groups certified at Miami convention.
Compounded drugs are dangerous concoctions, critics say.
Battling ageism in cancer negligence cases: many people view the elderly as having little to live for and even less to offer society. Uncovering...
Consortium claim goes forward even without wife's med-mal suit.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters